Synergy Pharmaceuticals (SGYP +5.3%) moves up after saying its commenced Phase IIb clinical trials of plecanatide, a treatment for patients with constipation-predominant irritable bowel syndrome. The trial is being conducted at 70 sites in the U.S. and includes 350 patients. Parexel International (PRXL -2%) is the contract research organization for the trial.
Synergy Pharmaceuticals (SGYP +5.3%) moves up after saying its commenced Phase IIb clinical...
Recommended For You
More Trending News
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SGYP-OLD | - | - |
Synergy Pharmaceuticals, Inc. |